AIR Trial: A study investigating a new drug, C21, in people with Idiopathic Pulmonary Fibrosis

Upcoming study
Expected to open November 2020
This study is currently recruiting
Expected to close March 2024
This study is closed
This study closed in March 2024
We will update this page with study results when available.
Information on study results are included below
This study closed in March 2024
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

The AIR Trial is investigating a new drug called compound 21 (C21) in people with IPF. This is a single treatment arm study, where all participants will take the drug.

Alveolar Epithelial Type II (AT2) cells, play a vital role in maintaining and repairing healthy lung tissue. People with IPF may have fewer of these AT2 cells, or the cells may not function correctly, which can promote scarring of the lungs. The new drug can attach to the surface of these cells and help to restore their normal function within the lungs.

The aim of the AIR Trial is to see if C21 can stabilise lung function in people with IPF and slow progression of the condition.

 – 

What is involved?

You will be asked to take the new drug twice per day for up to 36 weeks. Ongoing checks will be carried out by the researchers, to understand how your body responds to the drug. You will meet with the medical team every 12-weeks.

Summary of involvement

Taking a drug for up to 36 weeks

Medical assessments such as blood tests every 12 weeks

Can I take part?

You may be able to take part if you have received a diagnosis of IPF within the last 3 years and are age 40 years and above.

You will not be eligible to take part if you have previously taken, or are currently taking, Nintedanib or Pirfenidone.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the clinical trial team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Diagnosis of IPF within the last 3 years

Aged 40 and above

High resolution computed tomography (HRCT) scan within the last 36 months

Fully vaccinated against COVID-19

There is a set criteria for lung function, but this must be discussed with the research team

You will not be able to join the study of any of the following applies:

Previous use of nintedanib or pirfenidone

Smoking within the last 6 month (including e-cigarettes)

Body mass index (BMI) greater than 35 or less than 18

IPF exacerbation within the last 3 months

Other serious medical conditions

Cancer within the past 5 years

Treatment with certain medications within the past 2 and 4 weeks, as listed by the researchers

Pregnant or breastfeeding females

Males or females who are not willing to use contraceptive methods

What difference could taking part make?

People affected by IPF currently have limited treatment options to slow the progression of disease. New research studies such as this one, are needed to gain valuable knowledge about potentially better treatment options.

Taking part in the AIR Trial will help researchers to assess the tolerability and potential benefits of a new drug, C21. The study will help to gain greater understanding of C21 and if it has the potential to slow or stop the loss of lung function in people with IPF.

Taking part in research has the potential to make a difference for people who have IPF now and for future generations.

Where does the study take place?

Study locations

Birmingham

London

Manchester

How to take part

Please discuss this with your healthcare team and Consultant in the first instance, to express your interest in the study and hearing about opportunities to take part in research.

Further information

The summary on this page provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.

This study is supported by

Vicore Pharma AB
Orphan Reach
Study ID number:
NCT04533022

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org